Log in
Enquire now
‌

Isoplexis Corporation SBIR Phase I Award, September 2018

A SBIR Phase I contract was awarded to Isoplexis in September, 2018 for $224,633.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health.

OverviewStructured DataIssuesContributors

Contents

sbir.gov/node/1570645
Is a
SBIR/STTR Awards
SBIR/STTR Awards

SBIR/STTR Award attributes

SBIR/STTR Award Recipient
Isoplexis
Isoplexis
0
Government Agency
0
Government Branch
National Institutes of Health
National Institutes of Health
0
Award Type
SBIR0
Contract Number (US Government)
1R44CA224505-01A10
Award Phase
Phase I0
Award Amount (USD)
224,6330
Date Awarded
September 12, 2018
0
End Date
March 11, 2019
0
Abstract

Although signal transduction inhibitors occasionally offer clinical benefit for cancer patientssignal flux emanating from oncogenes is often distributed through multiple pathwayspotentially underlying the resistance which causes failure of most such inhibitorsMeasuring signal flux through multiple pathwaysin response to signal transduction inhibitorsmay help uncover network interactions that contribute to therapeutic resistance and that are not predicted by analyzing pathways in isolationProtein protein interactions within signaling pathways are often elucidated by assessing the levels of relevant pathway proteins in model and tumor derived cell lines and with various genetic and molecular perturbationsSuch interactionsand the implied signaling networksmay also be elucidated via quantitative measurements of multiple pathway related proteins within single cellsAt the single cell levelinhibitory and activating protein protein relationshipsas well as stochasticsingle cellfluctuationsare revealedHowevermost techniques for profiling signaling pathways require large numbers of cellsand bulk measurements have proven insufficient to detect secondary pathways post resistanceSinglecell immunostaining is promisingand some flow cytometry techniques are relevantyet limited in finding possible pathways due to intracellular multiplexing limitationsWe describe quantitativemultiplex assays of intracellular signaling proteins from single cancer cells using a platform called the single cell barcode chipSCBCThe SCBC is simple in conceptA single or defined number of cells is isolated within a microchamber that contains a sensitive antibody array specific for the capture and detection of a panel of proteinsThe SCBC design permits lysis of each individual trapped cellIntracellular staining flow cytometry can assay up tophosphoproteins from single cellsOur SCBC can profile a significantly larger panelup todifferent phosphoproteinswithsingle cells per chip for a statistically representative analysis of the sample populationThis new high multi plexed single cell phosphoproteomics analysis tool provides an analytical approach for detecting changes in signal coordination by monitoring phosphoproteinson a much larger scaleThis approach may identify actionable alterations in signal coordination that underlie adaptive resistancewhich can be suppressed through combination drug therapyincluding nonobvious drug combinationsSPECIFIC AIMDevelop a robust microchamber array flow cell that can be easily incorporated into larger automated workflow device for analysis of intracellular protein targetsSPECIFIC AIMDouble multiplexing capability of high density barcode SCBC chip by monitoring both intracellular proteins and metabolites simultaneouslyPerform single cellplex measurement for more comprehensive GBM pathway analysisSPECIFIC AIMImprove consumable to performflow cellin cartridge lysisdetection and washing capabilities for automationDevelop fully automated device workflowSPECIFIC AIMbDemonstrate utility of device in patient clinical trials as a commercial tool Although signal transduction inhibitors occasionally offer clinical benefit for cancer patientssignal flux emanating from oncogenes is often distributed through multiple pathwayspotentially underlying the resistance which causes failure of most such inhibitorsWe developed a new high multi plexed single cell intracellular analysis tool that provides an analytical approach for detecting changes in signal coordination by monitoring phosphoproteins and metaboliteson a much larger scaleWe propose to further developstandardize and scale this technology for commercialization as a clinical tool for developing combination drug therapies for glioblastoma patients

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like Isoplexis Corporation SBIR Phase I Award, September 2018

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.